Stocks
Liminatus Pharma, Inc.LIMN
NASDAQHealthcareBiotechnology$3.11
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for inflammatory and autoimmune diseases. Its lead candidates target complement-mediated pathways, with early-stage trials in dermatology and nephrology. Investors track LIMN for its pipeline catalysts and potential partnerships in the immunology space.
52W Range: $3.01-$141.50
Congressional Interest in Liminatus Pharma, Inc. (LIMN)
No congressional trades have been disclosed for Liminatus Pharma, Inc. (LIMN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading LIMN?
No congressional trades found for this stock.